Tagged with AZ

Ukraine Evgeniy Gaydukov, Country Director of AstraZeneca Ukraine, provides insights into the remarkable growth that the science-led, innovative company has been experiencing in Ukraine despite the unstable economic situation in the country, as well as the socially oriented, collaborative, and patient-centric approach he has been bolstering since taking over the helm…

Switzerland Markus Arigoni, CEO of Ticino-based micronization specialists Micro-Macinazione, describes the scope of the company’s operations, the enlargement of the firm’s R&D capacities, and emerging trends in the micronization niche. Micro-Macinazione SA was founded back in 1970 and has subsequently developed into one of Europe’s most renowned providers of micronization of…

Hungary Hungarian collector and producer of blood plasma and plasma-derived therapies HUMAN BioPlazma is rooted in over 60 years of history within the country, but only in 2008, with the influence and support of Italy-based Kedrion Biopharma has the company been able to transform into the powerhouse that is today.  …

Ireland Alan MacNeice, Executive Director and Site Leader at Jazz Pharmaceuticals, highlights the strategic importance of the Athlone site as the company’s first purpose-built, directly owned, managed and operated manufacturing facility; the special design of the facility catering to Jazz Pharmaceuticals business model; the importance of their human resource (HR) activities…

Pharma The Managing Director of HUMAN BioPlazma, Ákos Tóth, highlights the transformational growth that the business has experienced since becoming a part of Kedrion Biopharma in 2008, while pinpointing the strategic role that the subsidiary now plays in producing and distributing the company’s lifesaving biotherapies both inside and outside of Hungary.…

Pharma Charles-Henri Bodin, General Manager of Pierre Fabre, explains how the recent agreement with Pfizer on Toviaz will enlarge their footprint in Italy and how partnerships will play an increasing role in future growth. You’ve been with PF since 1999, serving in various positions in France and Italy before becoming GM…

Pharma The Dedicated Chair of the Pharmaceutical Committee of the Association of Health Insurance Companies speaks about drug pricing procedures, the partnership with the pharmaceutical industry, as well as her overarching vision for the organization. The Association of Health Insurance Companies of the Czech Republic (CR CAP) was established in 1997…

Pharma The general manager of IMS Health, Zsolt Szepesházi, explains how the current limitations of Hungary’s healthcare system have shifted the way that pharmaceutical companies approach the market, placing a much greater emphasis on value demonstration and patient-level data. You have been General Manager at IMS Health for 8 years. During…

Pharma Mario Marazziti, President of the Italian XII Social Affairs Commission, discusses new legislation relating to clinical risk, the effects of the 2014 Pact for Health, and the efficiency of Italian healthcare in general. You were recently highly instrumental in the passing of new legislation relating to clinical risk. Could you…

Pharma Mr. Aldo Braca discusses the competitive CDMO landscape in Italy, the importance of nurturing a community of employees, and the optimistic growth trend for the company powered by investment and innovation. This year, BSP celebrated its ten-year anniversary, congratulations! What were the key objectives that you have accomplished since the…

Pharma Pier Mannuccio Mannucci, Scientific Director of the Policlinico Foundation, describes some of the challenges the scientific community currently faces in Italy and what actions need to be taken to overcome these. He goes on to discuss the main objectives of the foundation and how the recent restructuring will provide better…

Pharma After choosing Egypt as the first country to host a production plant in the Middle East, AstraZeneca is interested in strengthening its foothold in the market. The country president discusses the challenges the company is facing as well as the initiatives in place to increase market access and affordability. Could…